Address: 1 Broadway, Cambridge, MA02142 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
Date: Saturday, June 3rd, 2023
Location: Boston Marriott Cambridge
Date: June 5-8, 2023
Location: Boston, MA
Booth: 2275-J
As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S. - West Coast)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Cancer Type | Cell Lines |
Colon cancer | PDXM-008C, PDXM-016C, PDXM-020C, PDXM-021C, PDXM-057C, PDXM-060C, PDXM-075C, PDXM-076C, PDXM-087C, PDXM-104C, PDXM-095C, PDXM-084C, PDXM-072C, PDXM-069C, PDXM-057C, PDXM-015C, PDXM-002C, |
Lung cancer | PDXM-054Lu, PDXM-050Lu, PDXM-047Lu, PDXM-053Lu, PDXM-028Lu, |
Gastric cancer | PDXM-092Ga, PDXM-091Ga, |
Breast cancer | PDXM-201B, PDXM-202B, PDX-203B |
Liver cancer | PDXM-211Li, PDXM-212Li |
Pancreas cancer | PDXM-221Pa, PDXM-222Pa |
Bladder Cancer | PDXM-231U, PDXM-232U |
Lymphoma | PDXM-241Ly, PDXM-242Ly |
The PDX model, as known as the patient derived tumor xenograft (PDX) model, is a model constructed by directly transplanting tumor tissue from a tumor patient into a severely immunodeficient mouse and making the tumor tissue grow in the mouse.
There is no in vitro culture process to "screen" tumors
Maintain the original characteristics and heterogeneity of the tumor
Maintain the consistency at the biology level of tumor molecular
Preserve the original non-tumor stroma and microenvironment
Patient-derived tumors can be studied in a variety of conditions
• New drug development
In particular, patient screening and predictive biomarker study in clinical trials of tumor immune-targeted drugs. The efficacy evaluation results of PDX and clinical similarity reached 87% (CDX only 5%).
• Personalized Medicine:
PDX model can be used to conduct PD evaluation experiments for tumor patients, which can be used for drug reference for clinical tumor patients.
• Molecular Marker development (Biomarker)
Drug reaction -- Molecular biological mechanisms